Search clinical trials for: GLPG3667

Total 10 results

Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Healthy

United Kingdom
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)

Systemic Lupus Erythematosus

United States, Spain, Bulgaria, France, Georgia, Argentina, Poland, Hungary, Germany, Chile
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

Dermatomyositis

United States, Belgium, Italy, Chile, Spain, Poland, United Kingdom, Bulgaria, Romania, Croatia, Czechia, France, Argentina
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Healthy

Belgium
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Poland, Slovakia, Bulgaria
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Healthy

Belgium
Galapagos NV

Completed

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Cystic Fibrosis

Belgium
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

Healthy

United Kingdom
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects

Healthy

Canada

3

Subscribe